James B Caress1, Stephanie L Ciarlone2, Elizabeth A Sullivan3, Leah P Griffin4, Michael S Cartwright1. 1. Department of Neurology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. 2. Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA. 3. Neurology Associates, Hattiesburg, Mississippi, USA. 4. Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Abstract
INTRODUCTION: Muscle cramping is a common symptom in amyotrophic lateral sclerosis (ALS) that lacks efficacious treatment. The natural history of this symptom is unknown, which hampers efforts to design optimal clinical trials. METHODS: We surveyed early stage ALS patients about their experience with cramps each month by phone for up to 21 months. RESULTS: Cramps developed in 95% of patients over the course of their disease. The number of cramps experienced by an individual varied widely from month-to-month and trended lower after the first year of illness (P = 0.26). Those with limb-onset and age >60 years had more cramps than bulbar-onset (P < 0.0001) and younger patients (P < 0.0001). CONCLUSIONS: The high variability of the number of cramps experienced suggests that clinical trials will need to use crossover designs or large numbers of participants, even when the treatment effect is substantial.
INTRODUCTION: Muscle cramping is a common symptom in amyotrophic lateral sclerosis (ALS) that lacks efficacious treatment. The natural history of this symptom is unknown, which hampers efforts to design optimal clinical trials. METHODS: We surveyed early stage ALSpatients about their experience with cramps each month by phone for up to 21 months. RESULTS:Cramps developed in 95% of patients over the course of their disease. The number of cramps experienced by an individual varied widely from month-to-month and trended lower after the first year of illness (P = 0.26). Those with limb-onset and age >60 years had more cramps than bulbar-onset (P < 0.0001) and younger patients (P < 0.0001). CONCLUSIONS: The high variability of the number of cramps experienced suggests that clinical trials will need to use crossover designs or large numbers of participants, even when the treatment effect is substantial.
Authors: R G Miller; D Moore; L A Young; C Armon; R J Barohn; M B Bromberg; W W Bryan; D F Gelinas; M C Mendoza; H E Neville; G J Parry; J H Petajan; J M Ravits; S P Ringel; M A Ross Journal: Neurology Date: 1996-12 Impact factor: 9.910
Authors: S P Ringel; J R Murphy; M K Alderson; W Bryan; J D England; R G Miller; J H Petajan; S A Smith; R I Roelofs; F Ziter Journal: Neurology Date: 1993-07 Impact factor: 9.910
Authors: Helen E Stephens; Nanette C Joyce; Björn Oskarsson Journal: Amyotroph Lateral Scler Frontotemporal Degener Date: 2016-12-15 Impact factor: 4.092
Authors: Björn Oskarsson; Dan Moore; Tahseen Mozaffar; John Ravits; Martina Wiedau-Pazos; Nicholas Parziale; Nanette C Joyce; Ross Mandeville; Namita Goyal; Merit E Cudkowicz; Michael Weiss; Robert G Miller; Craig M McDonald Journal: Muscle Nerve Date: 2018-03-06 Impact factor: 3.217
Authors: Colin J Mahoney; Rebekah M Ahmed; William Huynh; Sicong Tu; Jonathan D Rohrer; Richard S Bedlack; Orla Hardiman; Matthew C Kiernan Journal: CNS Drugs Date: 2021-05-15 Impact factor: 5.749
Authors: Anthony Tucker-Bartley; Jordan Lemme; Andrea Gomez-Morad; Nehal Shah; Miranda Veliu; Frank Birklein; Claudia Storz; Seward Rutkove; David Kronn; Alison M Boyce; Eduard Kraft; Jaymin Upadhyay Journal: Neurosci Biobehav Rev Date: 2021-02-10 Impact factor: 9.052